# InnFocus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innfocus

- Industry: Medical Devices & Equipment
- Headquarters: Miami, US
- Website: www.innfocusinc.com
- Total disclosed funding: $35M
- Latest round: Series C (Sep 30, 2015)
- Investors on record: 4

## About

InnFocus, Inc. specializes in developing innovative solutions for glaucoma treatment, utilizing unique biomaterials to enhance surgical outcomes and patient care in ophthalmology.InnFocus, Inc. was founded in 2003 and is headquartered in Miami, US. The company focuses on creating medical devices for managing intraocular pressure in glaucoma patients. In July 2016, InnFocus raised USD 225 mn in funding from Santen Pharmaceutical Co., Ltd. The total amount raised by the company is also USD 225 mn, reflecting the significant investment interest in their technology. InnFocus has successfully completed 4 deals to date.InnFocus, Inc. primarily focuses on developing innovative products for glaucoma treatment through the use of SIBS (poly[styrene-block-isobutylene-block-styrene]), a proprietary biomaterial. Their core offerings include surgical implants designed to effectively manage intraocular pressure for glaucoma patients, enhancing clinical outcomes while reducing complication risks associated with traditional materials. The products have undergone rigorous testing since the company’s inception, targeting critical markets in North America, Europe, and parts of Asia, and are sold to healthcare providers, hospitals, and surgical centers.InnFocus generates revenue primarily through the sale of its glaucoma surgical implants to healthcare institutions and professionals in the ophthalmology sector. The company engages in direct sales to hospitals and surgical centers, where their products are integrated into treatment plans for glaucoma patients. The pricing structure reflects the advanced technology of their flagship products, which leverage the properties of SIBS and are positioned as premium solutions, catering to healthcare providers' needs.InnFocus plans to utilize its recent funding of USD 225 mn to develop new treatment options for glaucoma. The company is focused on introducing innovative products to the market to enhance patient care. Additionally, InnFocus aims to expand its reach into new geographic regions, specifically targeting markets in Asia and Europe, with plans to launch these initiatives by 2025.

## Funding rounds

- Series C, Sep 30, 2015, $33M — Saints Capital, Hoya Corporation, Crown Venture Funds, Santen Pharmaceutical Co., Ltd.
- Series A, Jun 28, 2011, $2M — Saints Capital

## Investors

- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series A, Series C
- Hoya Corporation — Series C
- Crown Venture Funds — Series C
- Santen Pharmaceutical Co., Ltd. — Series C